MTOR and neoplasm: Specific genetic alterations like activating mutations in the cyclin dependent kinase (CDK) or mechanistic Target of Rapamycin (mTOR) pathway were identified in the BM but absent in the matched primary tumor, indicating that these specific mutations might be associated with BM progression and therefore emerging targets for BM specific therapies [26].